USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
19 - 22 Oct 2025 | Las Vegas

AI's Mission to the Medical Margins

Keep exploring for FREE!

Create a free account or log in to unlock content, event past recordings and more!

Speakers:

Aliza Apple Vice President, Catalyze360 AI/ML Eli Lilly and Company
Aliza Apple
Vice President, Catalyze360 AI/ML Eli Lilly and Company
Jessica Federer Managing DirectorThe Women's Health Fund
Jessica Federer
Managing DirectorThe Women's Health Fund
Mathai Mammen CEO, President & ChairmanParabilis Medicines
Mathai Mammen
CEO, President & ChairmanParabilis Medicines
Matthias Kleinz Executive Vice PresidentUPMC Enterprises
Matthias Kleinz
Executive Vice PresidentUPMC Enterprises

About this Session:

While everyone's watching AI revolutionize cancer and Alzheimer's research, a quieter revolution is happening in medicine's forgotten corners: rare diseases, renal conditions, and other "orphan" illnesses that have been largely ignored by pharma because the patient populations were too small and the profit margins too uncertain. AI is flipping this script entirely, using computational power to tackle diseases that affect thousands rather than millions, proving that machine learning doesn't care about market size when it comes to identifying promising drug targets and accelerating discovery timelines. From predicting how novel compounds might treat rare genetic disorders to designing therapies for chronic kidney disease that affects 37 million Americans, but receives a fraction of the research attention, AI platforms are democratizing drug discovery for conditions that traditional pharmaceutical economics left behind. Are we on the verge of a golden age for rare disease treatment, where computational drug discovery finally levels the playing field and ensures that rare doesn't mean forgotten?